These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 30246405)
1. Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines. Sakai K; Maeda S; Saeki K; Nakagawa T; Murakami M; Endo Y; Yonezawa T; Kadosawa T; Mori T; Nishimura R; Matsuki N Vet Comp Oncol; 2018 Dec; 16(4):642-649. PubMed ID: 30246405 [TBL] [Abstract][Full Text] [Related]
2. Anti-tumour effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines. Kaji K; Motegi T; Yonezawa T; Momoi Y; Maeda S Open Vet J; 2024 May; 14(5):1259-1268. PubMed ID: 38938437 [TBL] [Abstract][Full Text] [Related]
3. Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo. Sakai K; Kato D; Yoshinaka J; Takahashi Y; Ikeda N; Aoki S; Iguchi T; Ishikawa S; Yamagishi N; Shimamura S; Nakagawa T Vet Comp Oncol; 2024 Jun; 22(2):230-238. PubMed ID: 38502572 [TBL] [Abstract][Full Text] [Related]
4. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. Cronise KE; Hernandez BG; Gustafson DL; Duval DL Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548 [TBL] [Abstract][Full Text] [Related]
5. Hedgehog signaling is activated in canine transitional cell carcinoma and contributes to cell proliferation and survival. Gustafson TL; Kitchell BE; Biller B Vet Comp Oncol; 2017 Mar; 15(1):174-183. PubMed ID: 25864514 [TBL] [Abstract][Full Text] [Related]
6. Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma. Yokota S; Yonezawa T; Momoi Y; Maeda S J Vet Med Sci; 2022 May; 84(5):666-674. PubMed ID: 35387955 [TBL] [Abstract][Full Text] [Related]
7. Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder. Tsuboi M; Sakai K; Maeda S; Chambers JK; Yonezawa T; Matsuki N; Uchida K; Nakayama H Vet Pathol; 2019 May; 56(3):369-376. PubMed ID: 30612533 [TBL] [Abstract][Full Text] [Related]
8. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma. Guo XF; Zhu XF; Zhong GS; Deng BG Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639 [TBL] [Abstract][Full Text] [Related]
9. Effects of calcitriol, seocalcitol, and medium-chain triglyceride on a canine transitional cell carcinoma cell line. Kaewsakhorn T; Kisseberth WC; Capen CC; Hayes KA; Calverley MJ; Inpanbutr N Anticancer Res; 2005; 25(4):2689-96. PubMed ID: 16080513 [TBL] [Abstract][Full Text] [Related]
10. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Lin TY; Zhang H; Wang S; Xie L; Li B; Rodriguez CO; de Vere White R; Pan CX Mol Cancer; 2011 Jan; 10(1):9. PubMed ID: 21272294 [TBL] [Abstract][Full Text] [Related]
11. Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder. Arnold EJ; Childress MO; Fourez LM; Tan KM; Stewart JC; Bonney PL; Knapp DW J Vet Intern Med; 2011; 25(6):1385-90. PubMed ID: 22092632 [TBL] [Abstract][Full Text] [Related]
12. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts. Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202 [TBL] [Abstract][Full Text] [Related]
13. Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. Vinall RL; Kent MS; deVere White RW Am J Vet Res; 2012 Oct; 73(10):1626-33. PubMed ID: 23013190 [TBL] [Abstract][Full Text] [Related]
14. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713 [TBL] [Abstract][Full Text] [Related]
15. Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development. Knapp DW; Ramos-Vara JA; Moore GE; Dhawan D; Bonney PL; Young KE ILAR J; 2014; 55(1):100-18. PubMed ID: 24936033 [TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells. Iizuka K; Shoji K; Fujiyuki T; Moritoh K; Tamura K; Yoshida A; Sato H; Yoneda M; Asano K; Kai C Res Vet Sci; 2020 Dec; 133():313-317. PubMed ID: 33183781 [TBL] [Abstract][Full Text] [Related]
17. Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs. Maeda S; Sakai K; Kaji K; Iio A; Nakazawa M; Motegi T; Yonezawa T; Momoi Y Sci Rep; 2022 Jan; 12(1):4. PubMed ID: 35027594 [TBL] [Abstract][Full Text] [Related]
18. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. Greene SN; Lucroy MD; Greenberg CB; Bonney PL; Knapp DW J Am Vet Med Assoc; 2007 Oct; 231(7):1056-60. PubMed ID: 17916030 [TBL] [Abstract][Full Text] [Related]
20. Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer. Bai M; Song N; Che X; Wang X; Qu X; Liu Y Cell Biol Int; 2018 Jul; 42(7):781-793. PubMed ID: 29271513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]